Skip to main content
. 2022 Jun 1;27(9):740–750. doi: 10.1093/oncolo/oyac082

Table 4.

Multivariable survival analysis stratified by stage and status in terms of chemotherapy for stage III low risk.

Overall survival (years from diagnosis)
Covariate Level N Hazard ratio (95% CI) HR P-value
Chemotherapy type No chemo 9867 2.49 (2.35-2.65) <.001
Single agent 3590 1.17 (1.09-1.25) <.001
Multiagent 5462 - -
Facility type Community cancer program 2464 1.10 (1.03-1.18) .007
Comprehensive Community cancer program 9311 1.01 (0.96-1.07) .674
Integrated network cancer program 2729 1.11 (1.04-1.19) .002
Academic/research program 4415 - -
Facility location Northeast 4116 0.97 (0.91-1.04) .375
South 6607 1.05 (0.98-1.11) .155
Midwest 5224 1.04 (0.97-1.11) .265
West 2972 NA NA
Sex Male 8155 1.26 (1.21-1.31) <.001
Female 10 764 NA NA
Median income quartiles 2000 <$30 000 2575 1.09 (1.02-1.17) .017
$30 000-$34 999 3459 1.07 (1.01-1.14) .024
$35 000-$45 999 5486 1.03 (0.98-1.09) .206
≥$46 000 7399 NA NA
Urban/rural 2003 Urban 2235 1.01 (0.94-1.08) .843
Rural 961 0.89 (0.81-0.98) .020
Metro 15 723 NA NA
Grade Moderately differentiated, moderately well differentiated, and intermediate differentiation 12 862 1.01 (0.94-1.10) .751
Poorly differentiated 4114 1.08 (0.99-1.18) .084
Undifferentiated, anaplastic 587 1.07 (0.93-1.23) .355
Well differentiated, differentiated, and NOS 1356 NA NA
Race Black 1871 1.04 (0.97-1.12) .279
Other 715 0.86 (0.76-0.97) .014
White 16 333 NA NA
Hispanic ethnicity Yes 788 0.89 (0.80-1.00) .046
No 18 131 NA NA
Insurance type Not insured 93 1.31 (0.95-1.80) .098
Private insurance 1852 0.96 (0.89-1.03) .209
Government insurance 16 974 NA NA
Surgical margins Positive 714 1.55 (1.41-1.70) <.001
Negative 18 205 NA NA
Charlson-Deyo scores 1 5040 1.20 (1.15-1.26) <.001
≥2 2417 1.59 (1.51-1.69) <.001
0 11 462 NA NA
Age at diagnosis 18 919 1.04 (1.03-1.04) <.001